VYNE Therapeutics Inc.
Business
VYNE Therapeutics is a clinical-stage biopharmaceutical company developing small molecule BET inhibitors for inflammatory and immune-mediated conditions. The company holds exclusive worldwide rights to BET inhibitor compounds licensed from Tay Therapeutics. Product candidates include repibresib gel, a topical pan-BD BET inhibitor for vitiligo, and VYN202, an oral BD2-selective BET inhibitor for psoriasis and other immune-mediated inflammatory diseases. VYNE operates through contract manufacturing and development partnerships.
Summary from 10-K filed 2026-02-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 600,000 | 500,000 | 400,000 | 500,000 | 931,000 | |
| Research and development | 19 | 31 | 16 | 18 | 20 | |
| General and administrative | 11 | 13 | 13 | 16 | — | |
| Total operating expenses | 30 | 44 | 30 | 35 | 40 | |
| Operating loss | −30 | −44 | −29 | −34 | −39 | |
| Other income, net | 3 | 4 | 1 | 363,000 | −135,000 | |
| Loss from continuing operations before income taxes | −27 | −40 | −28 | −34 | −45 | |
| Income tax expense | 4,000 | 4,000 | 0 | 13,000 | −448,000 | |
| Loss from continuing operations | −27 | −40 | −28 | −34 | −44 | |
| Income (loss) from discontinued operations, net of income taxes | 253,000 | −27,000 | −580,000 | 11 | −29 | |
| Net loss | −27 | −40 | −28 | −23 | −73 | |
| Loss per share from continuing operations, basic (in dollars per share) | −0.63 | −0.93 | −2.72 | −10.65 | −15.46 | |
| Loss per share from continuing operations, diluted (in dollars per share) | −0.63 | −0.93 | −2.72 | −10.65 | −15.46 | |
| (Loss) income per share from discontinuing operations, basic (in dollars per share) | 0.01 | 0 | −0.06 | 3.37 | −10.18 | |
| (Loss) income per share from discontinuing operations, diluted (in dollars per share) | 0.01 | 0 | −0.06 | 3.37 | −10.18 | |
| Loss per share basic (in dollars per share) | −0.62 | −0.93 | −2.78 | −7.28 | −25.64 | |
| Loss per share diluted (in dollars per share) | −0.62 | −0.93 | −2.78 | −7.28 | −25.64 | |
| Weighted average shares outstanding - basic (in shares) | 43 | 43 | 10 | 3 | 3 | |
| Weighted average shares outstanding - diluted (in shares) | 43 | 43 | 10 | 3 | 3 | |
| Unrealized losses on marketable securities, net of tax of $0 | −18,000 | −6,000 | 26,000 | 0 | — | |
| Total other comprehensive loss | −18,000 | −6,000 | 26,000 | 0 | — | |
| Comprehensive loss | −27 | −40 | −28 | −23 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-09-30 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 24 | 20 | 31 | — | 31 | |
| Investment in marketable securities (Note 6) | 5 | 42 | 63 | — | 0 | |
| Prepaid and other current assets | 1 | 3 | 3 | — | 2 | |
| Total Current Assets | 30 | 64 | 96 | — | 38 | |
| Property and equipment, net (Note 7) | 90,000 | 113,000 | 0 | — | 0 | |
| Operating lease right of use assets (Note 9) | 0 | 93,000 | 207,000 | 200,000 | 0 | |
| Non-current prepaid expenses and other assets | 60,000 | 2 | — | — | — | |
| Total Non-current Assets | 150,000 | 2 | 2 | — | 2 | |
| Total Assets | 30 | 67 | 98 | — | 41 | |
| Trade payables | 1 | 3 | 2 | — | 2 | |
| Accrued expenses (Note 8) | 941,000 | 9 | 4 | — | 4 | |
| Employee-related obligations | 413,000 | 1 | 2 | — | 2 | |
| Operating lease liabilities (Note 9) | 0 | 99,000 | 115,000 | — | 0 | |
| Other current liabilities | 0 | 1 | 0 | — | — | |
| Total Current Liabilities | 2 | 15 | 8 | — | 9 | |
| Total Liabilities | 2 | 15 | 9 | — | 9 | |
| Commitments and Contingencies (Note 11) | — | — | — | — | — | |
| Preferred stock: $0.0001 par value; 20,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | — | 0 | |
| Common stock: $0.0001 par value; 150,000,000 shares authorized at December 31, 2025 and December 31, 2024; 33,323,171 and 14,830,013 shares issued and outstanding at December 31, 2025 and 2024, respectively | 3,000 | 1,000 | 1,000 | — | 0 | |
| Additional paid-in capital | 785 | 783 | 780 | — | 694 | |
| Accumulated other comprehensive income | 2,000 | 20,000 | 26,000 | — | 0 | |
| Accumulated deficit | −758 | −731 | −691 | — | −663 | |
| Total Shareholders' Equity | 28 | 52 | 89 | — | 31 | |
| Total Liabilities and Shareholders Equity | 30 | 67 | 98 | — | 41 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 23,000 | 4,000 | 0 | 72,000 | 100,000 | |
| Share-based compensation | 2 | 3 | 3 | 4 | 8 | |
| Amortization of premium or discount on marketable securities | −778,000 | −2 | −255,000 | 0 | — | |
| Unrealized loss on cash equivalents | 0 | −1,000 | 1,000 | 0 | 0 | |
| Trade receivables, prepaid expenses and other assets and operating lease right of use assets | 4 | −899,000 | 405,000 | 11 | 8 | |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | −12 | 6 | −559,000 | −9 | −3 | |
| Operating lease liabilities | −99,000 | −114,000 | 214,000 | −349,000 | −1 | |
| Net cash used in operating activities | −33 | −34 | −25 | −29 | −56 | |
| Purchase of property and equipment | 0 | −117,000 | 0 | — | — | |
| Proceeds from the sale and maturity of marketable securities | 68 | 84 | 0 | 0 | 1 | |
| Purchases of marketable securities | −31 | −61 | −62 | 0 | — | |
| Net cash provided by investing activities | 37 | 23 | −57 | 16 | 1 | |
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | −143,000 | −141,000 | −67,000 | −28,000 | — | |
| Net cash used in financing activities | −143,000 | −141,000 | 82 | 2 | 40 | |
| Increase (decrease) in cash and cash equivalents | 4 | −11 | −301,000 | — | — | |
| Issuance of vested shares under employee share purchase plan | 16,000 | 30,000 | 48,000 | 37,000 | 169,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is VYNE Therapeutics Inc.'s CIK number?
VYNE Therapeutics Inc.'s SEC CIK number is 0001566044 (1566044). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find VYNE Therapeutics Inc.'s SEC filings?
All of VYNE Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did VYNE Therapeutics Inc. last report earnings?
VYNE Therapeutics Inc. (VYNE) most recently filed an earnings 8-K with the SEC on Nov 6, 2025, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001566044-25-000007). This is VYNE Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is VYNE Therapeutics Inc.'s most recent earnings 8-K?
VYNE Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed Nov 6, 2025 under accession 0001566044-25-000007. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View VYNE Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →